After reviewing, you can save changes, download the form, print it for records, or share it as needed
The current status depends on which specific strengths and forms are in shortage and the outcome of ongoing legal proceedings
Lilly filed lawsuits to stop the unlawful marketing and sale of non-FDA approved compounded products fraudulently claiming to be Mounjaro [tirzepatide] by medical spas, wellness centers, and compounding pharmacies. Lilly provided a statement to KFVS, saying in an email, these entities should be stopped from providing drug products in violation of consumer protection laws, particularly where they promise their patients that their drugs offer the same safety profile and clinical benefits as Mounjaro. The company also said that products claiming to contain tirzepatide that are made and/or distributed by compounding pharmacies or distributed by counterfeit sources have not been reviewed by the FDA or global regulatory agencies for safety, quality, or efficacy and are not FDA-approved like Mounjaro, and may expose patients to potentially serious health risks

Un recente studio risponde alla nostra domanda: EFFETTI A LUNGO TERMINE DI SEMAGLUTIDE SULLA PERDITA DI PESO NELLOBESIT SENZA DIABETE NELLO STUDIO SELECT LONG-TERM WEIGHT LOSS EFFECTS OF SEMAGLUTIDE IN OBESITY WITHOUT DIABETES IN THE SELECT TRIAL Ryan DH, Lingvay I, Deanfield J, et al
Our pre-registration can be found at osf.io/7kmf5
Novo Nordisk is further along, having submitted oral semaglutide for FDA approval in obesity